200 related articles for article (PubMed ID: 30776546)
1. Access to second-line drug susceptibility testing results among patients with Rifampicin resistant tuberculosis after introduction of the Hain
Timire C; Sandy C; Kumar AMV; Ngwenya M; Murwira B; Takarinda KC; Harries AD
Int J Infect Dis; 2019 Apr; 81():236-243. PubMed ID: 30776546
[TBL] [Abstract][Full Text] [Related]
2. Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial.
Demers AM; Kim S; McCallum S; Eisenach K; Hughes M; Naini L; Mendoza-Ticona A; Pradhan N; Narunsky K; Poongulali S; Badal-Faesen S; Upton C; Smith E; Shah NS; Churchyard G; Gupta A; Hesseling A; Swindells S;
BMC Infect Dis; 2021 Feb; 21(1):205. PubMed ID: 33627075
[TBL] [Abstract][Full Text] [Related]
3. Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.
Pillay S; Steingart KR; Davies GR; Chaplin M; De Vos M; Schumacher SG; Warren R; Theron G
Cochrane Database Syst Rev; 2022 May; 5(5):CD014841. PubMed ID: 35583175
[TBL] [Abstract][Full Text] [Related]
4. Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study.
van Kampen SC; Tursynbayeva A; Koptleuova A; Murzakhmetova Z; Bigalieva L; Aubakirova M; Pak S; van den Hof S
PLoS One; 2015; 10(7):e0132514. PubMed ID: 26181578
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
[TBL] [Abstract][Full Text] [Related]
6. Impact of line probe assay-based molecular testing on individualized treatment in patients with rifampicin-resistant tuberculosis: data from the prospective INNOVA4TB cohort study in Ukraine.
Dudnyk A; Hempel M; Lytvyniuk O; Liudkevych H; Matsera V; Nikitchenko T; Blyzniuk S; Molina-Moya B; Preyer R; Domínguez J
Ther Adv Respir Dis; 2024; 18():17534666241249841. PubMed ID: 38817020
[TBL] [Abstract][Full Text] [Related]
7. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
Steingart KR; Schiller I; Horne DJ; Pai M; Boehme CC; Dendukuri N
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD009593. PubMed ID: 24448973
[TBL] [Abstract][Full Text] [Related]
8. Effect of the Xpert MTB/RIF on the detection of pulmonary tuberculosis cases and rifampicin resistance in Shanghai, China.
Wu Z; Rueda ZV; Li T; Zhang Z; Jiang Y; Sha W; Yu F; Chen J; Pan Q; Shen X; Yuan Z
BMC Infect Dis; 2020 Feb; 20(1):153. PubMed ID: 32070292
[TBL] [Abstract][Full Text] [Related]
9. Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study.
Jacobson KR; Barnard M; Kleinman MB; Streicher EM; Ragan EJ; White LF; Shapira O; Dolby T; Simpson J; Scott L; Stevens W; van Helden PD; Van Rie A; Warren RM
Clin Infect Dis; 2017 Jun; 64(11):1502-1508. PubMed ID: 28199520
[TBL] [Abstract][Full Text] [Related]
10. Epidemiological profile of multidrug-resistant and extensively drug-resistant Mycobacterium Tubrculosis among Congolese patients.
Elion Assiana DO; Abdul JBPA; Linguissi LSG; Epola M; Vouvoungui JC; Mabiala A; Biyogho CM; Ronald Edoa J; Adegbite BR; Adegnika AA; Elton L; Canseco JO; McHugh TD; Ahombo G; Ntoumi F
Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):84. PubMed ID: 34920727
[TBL] [Abstract][Full Text] [Related]
11. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
[TBL] [Abstract][Full Text] [Related]
12. The impact of expanded testing for multidrug resistant tuberculosis using genotype [correction of geontype] MTBDRplus in South Africa: an observational cohort study.
Hanrahan CF; Dorman SE; Erasmus L; Koornhof H; Coetzee G; Golub JE
PLoS One; 2012; 7(11):e49898. PubMed ID: 23226229
[TBL] [Abstract][Full Text] [Related]
13. Rifampicin Resistant Tuberculosis in Lesotho: Diagnosis, Treatment Initiation and Outcomes.
Katende B; Esterhuizen TM; Dippenaar A; Warren RM
Sci Rep; 2020 Feb; 10(1):1917. PubMed ID: 32024860
[TBL] [Abstract][Full Text] [Related]
14. Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing.
Chen J; Peng P; Du Y; Ren Y; Chen L; Rao Y; Wang W
BMC Infect Dis; 2017 Apr; 17(1):300. PubMed ID: 28438132
[TBL] [Abstract][Full Text] [Related]
15. Utility of the REBA MTB-Rifa® assay for rapid detection of rifampicin resistant Mycobacterium tuberculosis.
Cho E; Shamputa IC; Kwak HK; Lee J; Lee M; Hwang S; Jeon D; Kim CT; Cho S; Via LE; Barry CE; Lee JS
BMC Infect Dis; 2013 Oct; 13():478. PubMed ID: 24128118
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of drug-resistant tuberculosis in Zimbabwe: A health facility-based cross-sectional survey.
Timire C; Metcalfe JZ; Chirenda J; Scholten JN; Manyame-Murwira B; Ngwenya M; Matambo R; Charambira K; Mutunzi H; Kalisvaart N; Sandy C
Int J Infect Dis; 2019 Oct; 87():119-125. PubMed ID: 31357057
[TBL] [Abstract][Full Text] [Related]
17. Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia.
Ershova JV; Volchenkov GV; Somova TR; Kuznetsova TA; Kaunetis NV; Kaminski D; Demikhova OV; Chernousova LN; Vasilyeva IA; Kerr EM; Cegielski JP; Kurbatova EV
BMC Infect Dis; 2020 Jul; 20(1):543. PubMed ID: 32711457
[TBL] [Abstract][Full Text] [Related]
18. Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa.
Evans D; Schnippel K; Govathson C; Sineke T; Black A; Long L; Berhanu R; Rosen S
PLoS One; 2017; 12(7):e0181238. PubMed ID: 28746344
[TBL] [Abstract][Full Text] [Related]
19. The Xpert® MTB/RIF assay in routine diagnosis of pulmonary tuberculosis: A multicentre study in Lithuania.
Pimkina E; Zablockis R; Nikolayevskyy V; Danila E; Davidaviciene E
Respir Med; 2015 Nov; 109(11):1484-9. PubMed ID: 26403251
[TBL] [Abstract][Full Text] [Related]
20. Low prevalence of MDR-TB in Lao PDR: results from the first national anti-tuberculosis drug resistance survey.
Iem V; Dean A; Zignol M; Vongvichit P; Inthavong D; Siphanthong S; Sorsavanh T; Kim SJ; Shin S; Sébert J; Chittamany P
Trop Med Int Health; 2019 Apr; 24(4):421-431. PubMed ID: 30663180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
